



2024/3058

19.12.2024

DECISION OF THE EEA JOINT COMMITTEE No 204/2024

of 23 September 2024

**amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement
[2024/3058]**

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area ("the EEA Agreement"), and in particular Article 98 thereof,

Whereas:

- (1) Commission Implementing Decision (EU) 2024/734 of 27 February 2024 postponing the expiry date of the approval of brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flooumafen for use in biocidal products of product-type 14 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council ⁽¹⁾ is to be incorporated into the EEA Agreement.
- (2) Commission Implementing Decision (EU) 2024/731 of 28 February 2024 postponing the expiry date of the approval of indoxacarb for use in biocidal products of product-type 18 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council ⁽²⁾ is to be incorporated into the EEA Agreement.
- (3) Commission Implementing Decision (EU) 2024/732 of 28 February 2024 postponing the expiry date of the approval of aluminium phosphide for use in biocidal products of product-types 14 and 18 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council ⁽³⁾ is to be incorporated into the EEA Agreement.
- (4) Commission Implementing Decision (EU) 2024/733 of 28 February 2024 postponing the expiry date of the approval of cholecalciferol for use in biocidal products of product-type 14 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council ⁽⁴⁾ is to be incorporated into the EEA Agreement.
- (5) Commission Implementing Decision (EU) 2024/787 of 28 February 2024 postponing the expiry date of the approval of magnesium phosphide for use in biocidal products of product-type 18 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council ⁽⁵⁾ is to be incorporated into the EEA Agreement.
- (6) Commission Implementing Decision (EU) 2024/816 of 5 March 2024 addressing questions regarding the second comparative assessment of anticoagulant rodenticide biocidal products in accordance with Article 23(5) of Regulation (EU) No 528/2012 of the European Parliament and of the Council ⁽⁶⁾ is to be incorporated into the EEA Agreement.

⁽¹⁾ OJ L, 2024/734, 29.2.2024, ELI: http://data.europa.eu/eli/dec_impl/2024/734/oj.

⁽²⁾ OJ L, 2024/731, 1.3.2024, ELI: http://data.europa.eu/eli/dec_impl/2024/731/oj.

⁽³⁾ OJ L, 2024/732, 1.3.2024, ELI: http://data.europa.eu/eli/dec_impl/2024/732/oj.

⁽⁴⁾ OJ L, 2024/733, 1.3.2024, ELI: http://data.europa.eu/eli/dec_impl/2024/733/oj.

⁽⁵⁾ OJ L, 2024/787, 4.3.2024, ELI: http://data.europa.eu/eli/dec_impl/2024/787/oj.

⁽⁶⁾ OJ L, 2024/816, 7.3.2024, ELI: http://data.europa.eu/eli/dec_impl/2024/816/oj.

(7) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

Chapter XV of Annex II to the EEA Agreement shall be amended as follows:

1. The following point is inserted after point 12nnz (Commission Implementing Decision (EU) 2016/1175):

‘12nna. **32024 D 0816**: Commission Implementing Decision (EU) 2024/816 of 5 March 2024 addressing questions regarding the second comparative assessment of anticoagulant rodenticide biocidal products in accordance with Article 23(5) of Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2024/816, 7.3.2024).’

2. The following points are inserted after point 12zzzzzzzzzm (Commission Implementing Regulation (EU) 2024/893):

‘12zzzzzzzzzn. **32024 D 0734**: Commission Implementing Decision (EU) 2024/734 of 27 February 2024 postponing the expiry date of the approval of brodifacoum, bromadiolone, chlorophacinone, coumatetralyl, difenacoum, difethialone and flocoumafen for use in biocidal products of product-type 14 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2024/734, 29.2.2024).

12zzzzzzzzzo. **32024 D 0731**: Commission Implementing Decision (EU) 2024/731 of 28 February 2024 postponing the expiry date of the approval of indoxacarb for use in biocidal products of product-type 18 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2024/731, 1.3.2024).

12zzzzzzzzzp. **32024 D 0732**: Commission Implementing Decision (EU) 2024/732 of 28 February 2024 postponing the expiry date of the approval of aluminium phosphide for use in biocidal products of product-types 14 and 18 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2024/732, 1.3.2024).

12zzzzzzzzzq. **32024 D 0733**: Commission Implementing Decision (EU) 2024/733 of 28 February 2024 postponing the expiry date of the approval of cholecalciferol for use in biocidal products of product-type 14 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2024/733, 1.3.2024).

12zzzzzzzzzx. **32024 D 0787**: Commission Implementing Decision (EU) 2024/787 of 28 February 2024 postponing the expiry date of the approval of magnesium phosphide for use in biocidal products of product-type 18 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L, 2024/787, 4.3.2024).’

Article 2

The texts of Implementing Decisions (EU) 2024/734, (EU) 2024/731, (EU) 2024/732, (EU) 2024/733, (EU) 2024/787 and (EU) 2024/816 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

Article 3

This Decision shall enter into force on 24 September 2024, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*).

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

Done at Brussels, 23 September 2024.

For the EEA Joint Committee
The President
Anders H. EIDE

(*) No constitutional requirements indicated.